CYP7B1

Across TCGA pan-cancer cohorts, CYP7B1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CYP7B1 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CYP7B1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYP7B1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, PDAC, and COAD are the cancer types where CYP7B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.946	0.658	.010	14	view →
PDAC	DFS	Tertile	All	0.642	0.829	.010	13	view →
COAD	DFS	Tertile	II,III,IV	0.908	1.000	.042	12	view →
CCRCC	DFS	Tertile	IV	0.260	0.887	.024	10	view →
GBM	DFS	Quartile	All	0.497	0.266	.004	10	view →
LSCC	DFS	Quartile	II,III,IV	0.536	0.936	.016	6	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CYP7B1–LUAD (OS)

Open the LUAD breakdown →